Literature DB >> 11122906

Neuropsychiatric aspects of Parkinson's disease.

D Aarsland1, K Karlsen.   

Abstract

Previous studies of the neuropsychiatric aspects of Parkinson"s disease were frequently methodologically inadequate. Small sample sizes, selection bias, lack of diagnostic criteria of Parkinson"s disease, different definitions and assessment of neuropsychiatric symptoms, and lack of control groups seriously questioned the validity of and ability to generalize the results from many studies. During the past decade, however, several of these methodological issues have been addressed. Recent studies have found that mild cognitive impairment is very common, and dementia, depression, and psychotic symptoms develop in a large proportion of patients. Neuropsychiatric symptoms are important determinants of mortality and disease progression, as well as of the patients quality of life and course of disease, caregiver distress, and nursing home admission. Few adequately designed treatment trials have been published, but available evidence suggests that depression and hallucinations may be effectively treated using new antidepressants and atypical antipsychotic agents without worsening of parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11122906     DOI: 10.1007/s11920-999-0011-3

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  52 in total

1.  Progression of parkinsonian signs in Parkinson disease.

Authors:  E D Louis; M X Tang; L Cote; B Alfaro; H Mejia; K Marder
Journal:  Arch Neurol       Date:  1999-03

2.  Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series.

Authors:  I H Richard; A Maughn; R Kurlan
Journal:  Mov Disord       Date:  1999-01       Impact factor: 10.338

3.  Postmenopausal estrogen use and Parkinson's disease with and without dementia.

Authors:  K Marder; M X Tang; B Alfaro; H Mejia; L Cote; D Jacobs; Y Stern; M Sano; R Mayeux
Journal:  Neurology       Date:  1998-04       Impact factor: 9.910

4.  Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.

Authors:  J H Growdon; K Kieburtz; M P McDermott; M Panisset; J H Friedman
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

5.  Fatigue in patients with Parkinson's disease.

Authors:  K Karlsen; J P Larsen; E Tandberg; K Jørgensen
Journal:  Mov Disord       Date:  1999-03       Impact factor: 10.338

6.  Risk factors for depression in Parkinson disease.

Authors:  E Tandberg; J P Larsen; D Aarsland; K Laake; J L Cummings
Journal:  Arch Neurol       Date:  1997-05

7.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

8.  Treatment of depression in Parkinson's disease: a meta-analysis.

Authors:  T Klaassen; F R Verhey; G H Sneijders; N Rozendaal; H C de Vet; H M van Praag
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1995       Impact factor: 2.198

9.  Early dopaminergic drug-induced hallucinations in parkinsonian patients.

Authors:  C G Goetz; C Vogel; C M Tanner; G T Stebbins
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

10.  Psychotic symptoms in Parkinson's disease patients with dementia.

Authors:  D Naimark; E Jackson; E Rockwell; D V Jeste
Journal:  J Am Geriatr Soc       Date:  1996-03       Impact factor: 5.562

View more
  6 in total

1.  Health state values during the first year of drug treatment in early-stage Parkinson's disease: a prospective, population-based, cohort study.

Authors:  Corinna Vossius; Odd Bjarte Nilsen; Jan Petter Larsen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

2.  MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions.

Authors:  Mauricio P Cunha; Francis L Pazini; Vicente Lieberknecht; Josiane Budni; Ágatha Oliveira; Júlia M Rosa; Gianni Mancini; Leidiane Mazzardo; André R Colla; Marina C Leite; Adair R S Santos; Daniel F Martins; Andreza F de Bem; Carlos Alberto S Gonçalves; Marcelo Farina; Ana Lúcia S Rodrigues
Journal:  Mol Neurobiol       Date:  2016-10-08       Impact factor: 5.590

3.  Relationship between self-reported apathy and executive dysfunction in nondemented patients with Parkinson disease.

Authors:  Dennis J Zgaljardic; Joan C Borod; Nancy S Foldi; Mary Rocco; Paul J Mattis; Mark F Gordon; Andrew S Feigin; David Eidelberg
Journal:  Cogn Behav Neurol       Date:  2007-09       Impact factor: 1.600

Review 4.  Psychiatric aspects of Parkinson's disease.

Authors:  Sandeep Grover; Mansi Somaiya; Santhosh Kumar; Ajit Avasthi
Journal:  J Neurosci Rural Pract       Date:  2015-01

5.  Neuropsychiatric Symptoms in Parkinson's Disease Patients Are Associated with Reduced Health-Related Quality of Life and Increased Caregiver Burden.

Authors:  Hannah von Eichel; Johanne Heine; Florian Wegner; Sophia Rogozinski; Stephanie Stiel; Adrian Groh; Lea Krey; Günter U Höglinger; Martin Klietz
Journal:  Brain Sci       Date:  2022-01-11

6.  Study on the Regulation Effect of Optogenetic Technology on LFP of the Basal Ganglia Nucleus in Rotenone-Treated Rats.

Authors:  Zongya Zhao; Yanxiang Niu; Peiqi Chen; Yu Zhu; Liangliang Shi; Xuewei Zhao; Chang Wang; Yehong Zhang; Zhixian Gao; Wenshuai Jiang; Wu Ren; Renjun Gu; Yi Yu
Journal:  Neural Plast       Date:  2021-07-28       Impact factor: 3.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.